A5047327086- Ovarian cancer diagnosis and treatment
- Advanced Electron Microscopy Techniques and Applications
- PARP inhibition in cancer therapy
- Prostate Cancer Treatment and Research
- Gastric Cancer Management and Outcomes
- Metastasis and carcinoma case studies
- Spine and Intervertebral Disc Pathology
- Xenotransplantation and immune response
- Bladder and Urothelial Cancer Treatments
- Musculoskeletal pain and rehabilitation
- Medical Imaging Techniques and Applications
- Sperm and Testicular Function
- Multiple and Secondary Primary Cancers
- Genetic factors in colorectal cancer
- Radiomics and Machine Learning in Medical Imaging
- Cancer Research and Treatments
- Medical Imaging and Analysis
- Liver Disease Diagnosis and Treatment
- Healthcare Technology and Patient Monitoring
- Urinary and Genital Oncology Studies
Asahikawa Medical University
2025
Niigata University
2023
Shinshu University
2003
Ōtani University
2003
University of Occupational and Environmental Health Japan
1992
Saga Medical School Hospital
1990
Abstract BRCA1/2 mutations are robust biomarkers for platinum-based chemotherapy in epithelial ovarian cancers. However, clear cell carcinoma (CCC) less frequent compared with high-grade serous cancer (HGSC). The discovery of that can be applied to CCC is an unmet need chemotherapy. Schlafen 11 (SLFN11) has attracted attention as a novel sensitizer DNA-damaging agents including platinum. In this study, we investigated the utility SLFN11 HGSC and expression was analyzed retrospectively by IHC...
The immunocytochemical localization of alpha-fetoprotein (AFP)-producing cells was observed in pre- and postnatal carbon tetrachloride (CCl4)-treated rat livers comparison with that albumin (ALB)-producing cells. According to immunoblotting data, considerable numbers AFP-positive hepatocytes were the differentiating liver between prenatal day 19 0 (6 h after birth). Analyses by serial section profiles these revealed certain are also stained ALB antiserum. Immunoelectron microscopy...
<div>Abstract<p><i>BRCA1/2</i> mutations are robust biomarkers for platinum-based chemotherapy in epithelial ovarian cancers. However, <i>BRCA1/2</i> clear cell carcinoma (CCC) less frequent compared with high-grade serous cancer (HGSC). The discovery of that can be applied to CCC is an unmet need chemotherapy. Schlafen 11 (SLFN11) has attracted attention as a novel sensitizer DNA-damaging agents including platinum. In this study, we investigated the...
<p>Supplementary Figure Consort diagram of the cases used in this study.</p>
<p>Supplementary Figure Consort diagram of the cases used in this study.</p>
<div>Abstract<p><i>BRCA1/2</i> mutations are robust biomarkers for platinum-based chemotherapy in epithelial ovarian cancers. However, <i>BRCA1/2</i> clear cell carcinoma (CCC) less frequent compared with high-grade serous cancer (HGSC). The discovery of that can be applied to CCC is an unmet need chemotherapy. Schlafen 11 (SLFN11) has attracted attention as a novel sensitizer DNA-damaging agents including platinum. In this study, we investigated the...